Bavarian Nordic Lifts Guidance After Robust Q1 Call

Bavarian Nordic A/S ((BVNRY)) has held its Q1 earnings call. Read on for the main highlights of the call.

Bavarian Nordic’s latest earnings call struck an upbeat tone, with management leaning on strong first‑quarter numbers and contract wins to lift full‑year guidance. While timing issues and one‑off cash outflows weighed on reported metrics, executives stressed that core demand, manufacturing execution and public‑sector orders are robust enough to offset these temporary headwinds.

Strong Q1 Revenue and Upgraded Outlook

Bavarian Nordic reported Q1 revenue of DKK 1.058 billion, led by DKK 721 million from Travel Health and DKK 294 million from Public Preparedness. On the back of these results and fresh contracts, the company raised 2026 revenue guidance to DKK 5.5–5.7 billion and lifted its EBITDA margin target to about 28% from 25%.

Travel Health Growth and Product Momentum

Travel Health sales grew 14% year on year when adjusting for discontinued partner revenue, or 6% on a headline basis, underlining broad demand. Rabies vaccines rode strong market expansion in the U.S. at roughly 23% and Germany at about 29%, while Vivotif rebounded 12% and Encepur gained around one percentage point of share in a market growing close to 12%.

Vimkunya Launch Progress

New chikungunya vaccine Vimkunya continued its international rollout, generating DKK 41 million in Q1 after launches or approvals in roughly 14 markets including the U.S., Europe, the U.K., Belgium, the Netherlands and Switzerland. Management maintained its 2026 revenue goal of DKK 250 million for the product, framing Q1 as an early but encouraging indication of uptake.

Public Contracts and BARDA Order Support

Public Preparedness was again underpinned by long‑term government contracts, including a newly announced USD 97 million BARDA order that completes parts of an 11.5 million‑dose freeze‑dried program. Since 2017, more than USD 1.2 billion has been ordered under that framework, and for 2026 Bavarian Nordic has already secured DKK 2.0 billion of revenue with another DKK 300–500 million expected.

Profitability and Manufacturing Performance

The company posted Q1 EBITDA of DKK 165 million, equating to a 16% margin that aligns with normal seasonality, and a gross margin of 45%. Management highlighted increasingly stable manufacturing yields and site performance as key enablers for the higher full‑year margin ambition.

R&D Focus and Pipeline Milestones

R&D spending of DKK 175 million is concentrated on expanding Vimkunya’s label through pediatric, booster and efficacy work and on a Phase II study for transitioning smallpox vaccines to a cell line, with interim data targeted for late 2026. Defense‑funded equine encephalitis work is progressing and early Lyme and EBV projects are advancing, but with investment paced carefully.

Balance Sheet and Capital Allocation

Bavarian Nordic ended the quarter with about DKK 2.3 billion in cash, or roughly DKK 2.2 billion after the remaining share buyback, giving it room to fund operations and selective deals. Around DKK 350 million of a DKK 500 million buyback has been completed, and management reiterated that attractive M&A will take priority over additional capital returns.

U.S. Headwinds for Vimkunya

Despite the global rollout, Vimkunya’s U.S. trajectory is being held back by a delay in official publication of the CDC recommendation, which has led some wholesalers to hold off on stocking. Management cautioned that publication could take 12–18 months, creating both upside and downside risk versus the DKK 250 million revenue target if the delay persists.

Encepur Decline and Shelf‑Life Overhang

Encepur posted a 16% Q1 revenue decline as reported, though underlying demand and share trends were positive, because of wholesaler inventory timing and earlier short shelf‑life constraints. Bavarian Nordic released DKK 29 million of a prior provision in the quarter and expects a similar release in Q2, yet some stock may expire in early 2027, leaving residual uncertainty.

Lumpy Public Preparedness Revenues

Management reminded investors that Public Preparedness sales can swing sharply between quarters as vaccine deliveries follow government schedules rather than steady demand. Q1 revenues were lower than the prior year given phasing and outbreak‑related orders in 2025, so short‑term comparisons may not reflect the healthier multi‑year contract pipeline.

Negative Operating Cash Flow in Q1

Operating cash flow was negative DKK 752 million in the quarter, largely because of a milestone payment of more than DKK 500 million to a partner, which closes out that obligation. Management stressed that, given the sizeable cash balance and improving earnings, the cash outflow is viewed as a one‑off rather than a sign of underlying weakness.

Share Buyback Pace and Future Flexibility

The DKK 500 million share repurchase continues but has been constrained by safe‑harbor trading limits, leaving about DKK 150 million still to be deployed. Executives signaled that further buybacks beyond the current mandate remain an option, yet will be weighed against the timing of potential acquisitions and broader capital needs.

Deliberately Staged Pipeline Progression

Even with higher EBITDA guidance, the company is intentionally slowing the advance of some expensive clinical programs, notably Lyme and EBV vaccine candidates. This cautious stance is meant to protect margin targets and balance near‑term profitability with longer‑term innovation, though it may push out certain pipeline milestones.

Visibility and Uncertainty into 2027

Earlier‑than‑expected exercises of BARDA options and shifting schedules for bulk and drug‑substance deliveries are adding complexity to forecasts beyond 2026. Management still anticipates a more normalized Public Preparedness contribution of DKK 1.5–2.0 billion in 2027 absent outbreak‑driven demand, but acknowledged that exact phasing remains uncertain.

Guidance and Forward‑Looking Outlook

Looking ahead, Bavarian Nordic now expects 2026 revenue of DKK 5.5–5.7 billion and an EBITDA margin of roughly 28%, powered mainly by upgraded Public Preparedness guidance of DKK 2.3–2.5 billion while Travel Health targets are unchanged. The combination of a resilient Travel Health franchise, secured government contracts, strong cash reserves and active capital returns underpins management’s confidence in meeting the new targets.

Bavarian Nordic’s earnings call painted a picture of a vaccine specialist entering a more cash‑generative phase, supported by diversified products and long‑term public‑sector demand. While regulatory delays, shelf‑life issues and staged R&D spending introduce some bumps, investors heard a largely positive message of upgraded guidance, disciplined execution and optionality for future growth.